Breast Cancer-Related Lymphedema: Recent Updates on Diagnosis, Severity and Available Treatments.
Marco Pappalardo, Marta Starnoni, Gianluca Franceschini...
https://pubmed.ncbi.nlm.nih.gov/34065795/Actively Recruiting
Led by Pamukkale University · Updated on 2026-03-04
45
Participants Needed
1
Research Sites
N/A
Total Duration
Breast cancer is the most common cancer among women worldwide, and one of its major complications is breast cancer-related lymphedema BCRL. This condition can develop shortly after treatment or even years later, causing swelling, heaviness, discomfort, and reduced quality of life. Researchers are investigating how intermittent pneumatic compression IPC therapy compares to manual lymph drainage MLD, both standard parts of complete decongestive therapy CDT, to better understand IPCs role in treating BCRL. The study compares three groups one receiving the full CDT including MLD plus IPC, another receiving CDT without MLD but with IPC replacing it, and a third group receiving standard CDT with MLD alone. Treatments involve sessions five times a week for three weeks, using IPC at 20-50 mmHg pressure for 40 minutes per session when included. Total session durations vary from 75 to 115 minutes depending on the group and whether IPC is used alongside or instead of MLD. Participants will be monitored before and after the treatment period with measurements of arm volume and circumference, shoulder range of motion, and quality of life assessments. Other evaluations include questionnaires on arm function, swelling, heaviness, tightness, pain, and patient satisfaction. The study aims to assess acute effects within three weeks of starting rehabilitation, with all safety and outcome data collected under medical supervision.
CONDITIONS
Comparison of IPC Therapy as an Alternative or an Adjunct to MLD Within CDT for BCRL
E
Emre Bezmez, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pamukkale University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 weeks
Participants receive complete decongestive therapy with variations including manual lymph drainage and intermittent pneumatic compression, depending on their assigned group.
5 sessions per week
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Marco Pappalardo, Marta Starnoni, Gianluca Franceschini...
https://pubmed.ncbi.nlm.nih.gov/34065795/Diana J Dawes, Sarkis Meterissian, Mark Goldberg...
https://pubmed.ncbi.nlm.nih.gov/19020699/Sebnem Koldas Dogan, Saime Ay, Deniz Evcik...
https://pubmed.ncbi.nlm.nih.gov/20411289/G Szolnoky, B Lakatos, T Keskeny...
https://pubmed.ncbi.nlm.nih.gov/20218087/J Sitzia
https://pubmed.ncbi.nlm.nih.gov/7620649/Vaughan Keeley, Katie Riches, Leigh Ward...
https://pubmed.ncbi.nlm.nih.gov/37140559/Andrzej Szuba, Radha Achalu, Stanley G Rockson
https://pubmed.ncbi.nlm.nih.gov/12436430/M Pinto, F Gimigliano, F Tatangelo...
https://pubmed.ncbi.nlm.nih.gov/23698473/Hulya Uzkeser, Saliha Karatay, Burak Erdemci...
https://pubmed.ncbi.nlm.nih.gov/23925581/Susan G R McDuff, Amir I Mina, Cheryl L Brunelle...
https://pubmed.ncbi.nlm.nih.gov/30165125/Pamukkale University
Lead Sponsor